In conversation with... Takayuki Yoshino

from Listen to The Lancet Oncology · host The Lancet

Takayuki Yoshino (National Cancer Center Hospital East, Kashiwa, Japan) discusses the DESTINY-CRC01 trial on trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.

Episode metadata supplied by the publisher feed · Published Jun 2, 2021

Embed this episode

Attribution link and audio player

NOW PLAYING

In conversation with... Takayuki Yoshino

0:00 5:49

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Oncology?

This episode is 5 minutes long.

When was this Listen to The Lancet Oncology episode published?

This episode was published on June 2, 2021.

Can I download this Listen to The Lancet Oncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!